{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T22:37:13Z","timestamp":1762900633746},"reference-count":17,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,9,18]]},"DOI":"10.7759\/cureus.69625","type":"journal-article","created":{"date-parts":[[2024,9,18]],"date-time":"2024-09-18T07:28:37Z","timestamp":1726644517000},"source":"Crossref","is-referenced-by-count":1,"title":["Differences in Clinical Outcomes and Survival Among Primary, Secondary, and Concomitant Carcinoma In Situ of the Bladder"],"prefix":"10.7759","author":[{"given":"Shinro","family":"Hata","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Fujinami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mayuka","family":"Shinohara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinya","family":"Sejiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toru","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiromitsu","family":"Mimata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshitaka","family":"Shin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung H","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021, 71:209-49. 10.3322\/caac.21660","journal-title":"CA Cancer J Clin"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/nrurol.2017.16","article-title":"BCG-unresponsive non-muscle-invasive bladder cancer: recommendations from the IBCG","volume":"14","author":"Kamat AM","year":"2017","unstructured":"Kamat AM, Colombel M, Sundi D, et al.. BCG-unresponsive non-muscle-invasive bladder cancer: recommendations from the IBCG. Nat Rev Urol. 2017, 14:244-55. 10.1038\/nrurol.2017.16","journal-title":"Nat Rev Urol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2005.12.031","article-title":"Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials","volume":"49","author":"Sylvester RJ","year":"2006","unstructured":"Sylvester RJ, van der Meijden AP, Oosterlinck W, et al.. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 2006, 49:466-5; discussion 475-7. 10.1016\/j.eururo.2005.12.031","journal-title":"Eur Urol"},{"key":"ref4","article-title":"Carcinoma in situ","volume":"19","author":"Lamm DL","year":"1992","unstructured":"Lamm DL. Carcinoma in situ. Urol Clin North Am. 1992, 19:499-508.","journal-title":"Urol Clin North Am"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.euf.2019.04.002","article-title":"Recurrence rate and cost consequence of the shortage of Bacillus Calmette-Gu\u00e9rin Connaught strain for bladder cancer patients","volume":"7","author":"Ourfali S","year":"2021","unstructured":"Ourfali S, Ohannessian R, Fassi-Fehri H, Pages A, Badet L, Colombel M. Recurrence rate and cost consequence of the shortage of Bacillus Calmette-Gu\u00e9rin Connaught strain for bladder cancer patients. Eur Urol Focus. 2021, 7:111-6. 10.1016\/j.euf.2019.04.002","journal-title":"Eur Urol Focus"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software 'EZR' for medical statistics","volume":"48","author":"Kanda Y","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software 'EZR' for medical statistics. Bone Marrow Transplant. 2013, 48:452-8. 10.1038\/bmt.2012.244","journal-title":"Bone Marrow Transplant"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.21037\/tau.2020.03.40","article-title":"Clinical outcomes and survival differences between primary, secondary and concomitants carcinoma in situ of urinary bladder treated with BCG immunotherapy","volume":"9","author":"Piszczek R","year":"2020","unstructured":"Piszczek R, Krajewski W, Ma\u0142kiewicz B, Krajewski P, Tukiendorf A, Zdrojowy R, Ko\u0142odziej A. Clinical outcomes and survival differences between primary, secondary and concomitants carcinoma in situ of urinary bladder treated with BCG immunotherapy. Transl Androl Urol. 2020, 9:1338-44. 10.21037\/tau.2020.03.40","journal-title":"Transl Androl Urol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000150425.09317.67","article-title":"Bacillus Calmette-Guerin versus epirubicin for primary, secondary or concurrent carcinoma in situ of the bladder: results of a European Organization for the Research and Treatment of Cancer--Genito-Urinary Group Phase III Trial (30906)","volume":"173","author":"de Reijke TM","year":"2005","unstructured":"de Reijke TM, Kurth KH, Sylvester RJ, et al.. Bacillus Calmette-Guerin versus epirubicin for primary, secondary or concurrent carcinoma in situ of the bladder: results of a European Organization for the Research and Treatment of Cancer--Genito-Urinary Group Phase III Trial (30906). J Urol. 2005, 173:405-9. 10.1097\/01.ju.0000150425.09317.67","journal-title":"J Urol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1111\/j.1442-2042.2008.02012.x","article-title":"Clinical outcomes of bacillus Calmette-Gu\u00e9rin instillation therapy for carcinoma in situ of urinary bladder","volume":"15","author":"Takenaka A","year":"2008","unstructured":"Takenaka A, Yamada Y, Miyake H, Hara I, Fujisawa M. Clinical outcomes of bacillus Calmette-Gu\u00e9rin instillation therapy for carcinoma in situ of urinary bladder. Int J Urol. 2008, 15:309-13. 10.1111\/j.1442-2042.2008.02012.x","journal-title":"Int J Urol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2007.12.011","article-title":"The natural history of bladder carcinoma in situ after initial response to bacillus Calmette-G\u00faerin immunotherapy","volume":"27","author":"Gofrit ON","year":"2009","unstructured":"Gofrit ON, Pode D, Pizov G, Zorn KC, Katz R, Duvdevani M, Shapiro A. The natural history of bladder carcinoma in situ after initial response to bacillus Calmette-G\u00faerin immunotherapy. Urol Oncol. 2009, 27:258-62. 10.1016\/j.urolonc.2007.12.011","journal-title":"Urol Oncol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2010.03.032","article-title":"Clinical outcomes of primary bladder carcinoma in situ in a contemporary series","volume":"184","author":"Chade DC","year":"2010","unstructured":"Chade DC, Shariat SF, Godoy G, et al.. Clinical outcomes of primary bladder carcinoma in situ in a contemporary series. J Urol. 2010, 184:74-80. 10.1016\/j.juro.2010.03.032","journal-title":"J Urol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2011.05.045","article-title":"Long-term cancer-specific survival in patients with high-risk, non-muscle-invasive bladder cancer and tumour progression: a systematic review","volume":"60","author":"van den Bosch S","year":"2011","unstructured":"van den Bosch S, Alfred Witjes J. Long-term cancer-specific survival in patients with high-risk, non-muscle-invasive bladder cancer and tumour progression: a systematic review. Eur Urol. 2011, 60:493-500. 10.1016\/j.eururo.2011.05.045","journal-title":"Eur Urol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2013.07.102","article-title":"Defining progression in nonmuscle invasive bladder cancer: it is time for a new, standard definition","volume":"191","author":"Lamm D","year":"2014","unstructured":"Lamm D, Persad R, Brausi M, et al.. Defining progression in nonmuscle invasive bladder cancer: it is time for a new, standard definition. J Urol. 2014, 191:20-7. 10.1016\/j.juro.2013.07.102","journal-title":"J Urol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2014.01.006","article-title":"The economics of bladder cancer: costs and considerations of caring for this disease","volume":"66","author":"Svatek RS","year":"2014","unstructured":"Svatek RS, Hollenbeck BK, Holm\u00e4ng S, Lee R, Kim SP, Stenzl A, Lotan Y. The economics of bladder cancer: costs and considerations of caring for this disease. Eur Urol. 2014, 66:253-62. 10.1016\/j.eururo.2014.01.006","journal-title":"Eur Urol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2016.08.036","article-title":"Meta-analysis of the luminal and basal subtypes of bladder cancer and the identification of signature immunohistochemical markers for clinical use","volume":"12","author":"Dadhania V","year":"2016","unstructured":"Dadhania V, Zhang M, Zhang L, et al.. Meta-analysis of the luminal and basal subtypes of bladder cancer and the identification of signature immunohistochemical markers for clinical use. EBioMedicine. 2016, 12:105-17. 10.1016\/j.ebiom.2016.08.036","journal-title":"EBioMedicine"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-018-2397-1","article-title":"An increased body mass index is associated with a worse prognosis in patients administered BCG immunotherapy for T1 bladder cancer","volume":"37","author":"Ferro M","year":"2019","unstructured":"Ferro M, Vartolomei MD, Russo GI, et al.. An increased body mass index is associated with a worse prognosis in patients administered BCG immunotherapy for T1 bladder cancer. World J Urol. 2019, 37:507-14. 10.1007\/s00345-018-2397-1","journal-title":"World J Urol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3817","article-title":"Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity","volume":"15","author":"Knowles MA","year":"2015","unstructured":"Knowles MA, Hurst CD. Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity. Nat Rev Cancer. 2015, 15:25-41. 10.1038\/nrc3817","journal-title":"Nat Rev Cancer"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/296934-differences-in-clinical-outcomes-and-survival-among-primary-secondary-and-concomitant-carcinoma-in-situ-of-the-bladder","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,18]],"date-time":"2024-09-18T07:28:40Z","timestamp":1726644520000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/296934-differences-in-clinical-outcomes-and-survival-among-primary-secondary-and-concomitant-carcinoma-in-situ-of-the-bladder"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,18]]},"references-count":17,"URL":"https:\/\/doi.org\/10.7759\/cureus.69625","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9,18]]}}}